Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
ECTE's Cash to Debt is ranked higher than
92% of the 909 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. ECTE: No Debt )
ECTE' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: No Debt

Equity to Asset 0.85
ECTE's Equity to Asset is ranked higher than
90% of the 822 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ECTE: 0.85 )
ECTE' s 10-Year Equity to Asset Range
Min: 0.15   Max: 0.94
Current: 0.85

0.15
0.94
F-Score: 4
Z-Score: -12.07
M-Score: -1.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -74217.65
ECTE's Operating margin (%) is ranked lower than
56% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.67 vs. ECTE: -74217.65 )
ECTE' s 10-Year Operating margin (%) Range
Min: -300800   Max: 11.11
Current: -74217.65

-300800
11.11
Net-margin (%) -91429.41
ECTE's Net-margin (%) is ranked lower than
55% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. ECTE: -91429.41 )
ECTE' s 10-Year Net-margin (%) Range
Min: -246640   Max: -1.41
Current: -91429.41

-246640
-1.41
ROE (%) -94.24
ECTE's ROE (%) is ranked lower than
52% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.98 vs. ECTE: -94.24 )
ECTE' s 10-Year ROE (%) Range
Min: -251.11   Max: 1.95
Current: -94.24

-251.11
1.95
ROA (%) -79.65
ECTE's ROA (%) is ranked lower than
53% of the 913 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.21 vs. ECTE: -79.65 )
ECTE' s 10-Year ROA (%) Range
Min: -241.42   Max: 0.93
Current: -79.65

-241.42
0.93
ROC (Joel Greenblatt) (%) -895.58
ECTE's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.70 vs. ECTE: -895.58 )
ECTE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9177.57   Max: 27.45
Current: -895.58

-9177.57
27.45
Revenue Growth (%) -100.00
ECTE's Revenue Growth (%) is ranked lower than
53% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ECTE: -100.00 )
ECTE' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 44.2
Current: -100

0
44.2
EBITDA Growth (%) 8.70
ECTE's EBITDA Growth (%) is ranked higher than
75% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.30 vs. ECTE: 8.70 )
ECTE' s 10-Year EBITDA Growth (%) Range
Min: -53.4   Max: 14.6
Current: 8.7

-53.4
14.6
EPS Growth (%) 16.60
ECTE's EPS Growth (%) is ranked higher than
82% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. ECTE: 16.60 )
ECTE' s 10-Year EPS Growth (%) Range
Min: -49.2   Max: 1644.6
Current: 16.6

-49.2
1644.6
» ECTE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ECTE Guru Trades in Q4 2013

Jim Simons 115,287 sh (-6.72%)
» More
Q1 2014

ECTE Guru Trades in Q1 2014

Jim Simons 40,787 sh (-64.62%)
» More
Q2 2014

ECTE Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q3 2014

ECTE Guru Trades in Q3 2014

Jim Simons 10,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ECTE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.40
ECTE's P/B is ranked higher than
88% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. ECTE: 1.40 )
ECTE' s 10-Year P/B Range
Min: 0.25   Max: 30.39
Current: 1.4

0.25
30.39
P/S 795.60
ECTE's P/S is ranked lower than
57% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.94 vs. ECTE: 795.60 )
ECTE' s 10-Year P/S Range
Min: 7.58   Max: 2622.22
Current: 795.6

7.58
2622.22
EV-to-EBIT -1.10
ECTE's EV-to-EBIT is ranked lower than
55% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.43 vs. ECTE: -1.10 )
ECTE' s 10-Year EV-to-EBIT Range
Min: -33   Max: 0.1
Current: -1.1

-33
0.1
Current Ratio 0.94
ECTE's Current Ratio is ranked lower than
52% of the 892 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. ECTE: 0.94 )
ECTE' s 10-Year Current Ratio Range
Min: 0.02   Max: 27.55
Current: 0.94

0.02
27.55
Quick Ratio 0.94
ECTE's Quick Ratio is ranked higher than
55% of the 891 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. ECTE: 0.94 )
ECTE' s 10-Year Quick Ratio Range
Min: 0.02   Max: 27.55
Current: 0.94

0.02
27.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.56
ECTE's Price/Tangible Book is ranked higher than
58% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.32 vs. ECTE: 13.56 )
ECTE' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 451.11
Current: 13.56

0.42
451.11
Earnings Yield (Greenblatt) -95.60
ECTE's Earnings Yield (Greenblatt) is ranked lower than
55% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ECTE: -95.60 )
ECTE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1203.1   Max: 4882.5
Current: -95.6

1203.1
4882.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:XS5B.Germany,
Echo Therapeutics Inc was incorporated in Delaware in September 2007 under the name Durham Pharmaceuticals Acquisition Co. It is a medical device company with expertise in advanced skin permeation technology. The Companys medical device program is Symphony, a non-invasive, wireless, continuous glucose monitoring system designed to provide reliable, real-time glucose data conveniently, continuously and cost-effectively. The Symphony CGM System incorporates its SkinPrep device, transdermal glucose sensor, wireless transmitter and data display monitor. It is developing its Prelude SkinPrep System as a platform technology to allow for enhanced skin permeation that will enable two important applications; analyte extraction and needle-free drug delivery. It currently has two key strategic partnerships in place. It has granted Ferndale Pharma Group, Inc. a license to develop, market and sell the Prelude device for enhanced and needle-free delivery of topical anesthetics prior to needle insertion. It has also granted Handok Pharmaceuticals Co., Ltd. a license to develop, market and sell the Symphony CGM System for continuous glucose monitoring in South Korea. The Company competes with Edwards Lifesciences Corporation, Optiscan Biomedical Corp., Maquet Critical Care AB, Medtronic, Inc. A. Menarini Diagnostics S.r.l., Roche, Johnson & Johnson, Bayer and Abbott Laboratories. Government authorities in the United States, at the federal, state and local level, the European Union, and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion, advertising, distribution, marketing, export and import of products such as those the Company are developing.
» More Articles for ECTE

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 

More From Other Websites
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Dec 12 2014
ECHO THERAPEUTICS, INC. Financials Nov 27 2014
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 26 2014
10-Q/A for Echo Therapeutics, Inc. Nov 22 2014
10-Q for Echo Therapeutics, Inc. Nov 21 2014
ECHO THERAPEUTICS, INC. Files SEC form 10-Q/A, Quarterly Report Nov 20 2014
Echo Therapeutics Announces Third Quarter 2014 Financial Results Nov 19 2014
Echo Therapeutics Announces Third Quarter 2014 Financial Results Nov 19 2014
ECHO THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 19 2014
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 07 2014
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Nov 03 2014
Echo Therapeutics to Present Positive Clinical Trial Results at the 14th Annual Diabetes Technology... Nov 03 2014
Echo Therapeutics to Present Positive Clinical Trial Results at the 14th Annual Diabetes Technology... Nov 03 2014
Platinum Comments On Recent Statements Purportedly Made By Echo Therapeutics Oct 06 2014
Echo Therapeutics Comments On Special Meeting Proxy Contest Threatened By Platinum Management (NY)... Oct 06 2014
Echo Therapeutics Engages PricewaterhouseCoopers' Restructuring Practice to Explore Financial and... Oct 02 2014
Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And... Oct 02 2014
Echo Therapeutics Suspends Operations on Cash Concerns Sep 29 2014
Platinum Management (NY) LLC Calls for a Special Meeting of Stockholders at Echo Therapeutics, Inc. Sep 29 2014
ECHO THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Sep 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK